Venture-backed Argos Therapeutics raises $45 mln in IPO
Argos Therapeutics Inc, a biopharmaceutical company focused on immunotherapies for the treatment of cancer and infectious diseases, recently priced its initial public offering of 5,625 million shares of common stock at US$8.00 per share, giving the company US$45 million in proceeds. The Durham, North Carolina-based Agros has been listed on NASDAQ under the symbol ARGS. Founded in 1997, the company is venture-backed. Its most recent financing round, completed in Aug. 2013, raised US$42.5 million from an investor group that included Canadian venture capital firm Lumira Capital and pension fund manager the Caisse de dépôt et placement du Québec.
10 February 2014•2 mins read
